The Reasons Why Ovid Therapeutics’ Stock Outperformed Today

Ovid Therapeutics & Takeda Announce Agreement for Soticlestat

  • Ovid Pharmaceuticals is eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales
  • Potential first-in-class therapy reduced seizure frequency in children with Dravet syndrome and Lennox-Gastaut syndrome in Phase 2 ELEKTRA study
  • Original 2017 collaboration between Ovid and Takeda to conclude; Ovid will have no further development or milestone obligations
  • Takeda plans to initiate Phase 3 studies in children and . . .
    This content is for paid subscribers.
    Please click here to subscribe or here to log in.